ILEVRO is a Ophthalmic Suspension in the Human Prescription Drug category. It is labeled and distributed by Alcon Laboratories, Inc.. The primary component is Nepafenac.
Product ID | 0065-1750_36ff7e36-d529-4e61-ac2e-2e43d37629d8 |
NDC | 0065-1750 |
Product Type | Human Prescription Drug |
Proprietary Name | ILEVRO |
Generic Name | Nepafenac |
Dosage Form | Suspension |
Route of Administration | OPHTHALMIC |
Marketing Start Date | 2012-12-20 |
Marketing End Date | 2021-11-30 |
Marketing Category | NDA / NDA |
Application Number | NDA203491 |
Labeler Name | Alcon Laboratories, Inc. |
Substance Name | NEPAFENAC |
Active Ingredient Strength | 3 mg/mL |
Pharm Classes | Cyclooxygenase Inhibitors [MoA],Anti-Inflammatory Agents, Non-Steroidal [CS],Nonsteroidal Anti-inflammatory Drug [EPC] |
NDC Exclude Flag | N |
Marketing Start Date | 2012-12-20 |
Marketing End Date | 2021-11-30 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA203491 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2012-12-20 |
Marketing Category | NDA |
Application Number | NDA203491 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2012-12-20 |
Marketing Category | NDA |
Application Number | NDA203491 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2012-12-20 |
Ingredient | Strength |
---|---|
NEPAFENAC | 3 mg/mL |
SPL SET ID: | 6c212466-ff8d-ecfc-ede2-ef8bdcaaf114 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
PHarm Class EPC | |
NUI Code |
NDC | Brand Name | Generic Name |
---|---|---|
0065-1750 | ILEVRO | nepafenac |
0078-0743 | ILEVRO | nepafenac |
0065-0002 | NEVANAC | nepafenac |
0078-0778 | NEVANAC | nepafenac |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
ILEVRO 85716211 4397658 Live/Registered |
Novartis AG 2012-08-29 |